The Biostatistics Core (BC) provides expertise in biostatistics, clinical trials, and experimental design, as wellas supporting electronic data management for clinical research. Scientific consultation is provided by facultystatisticians who collaborate in the development of pilot projects, grant proposals and clinical protocols. TheBC statisticians help design research studies, and conduct interim and final data analyses. Core servicesinclude the development of case-report forms, databases and data entry tools to initiate clinical protocols, aswell as access to clinical research and cancer registry data repositories for retrospective research. The Coreprovides expertise and access to a variety of technologies, including modern statistical computingenvironments such as SAS, JMP, Splus, and R; specialized statistical computing tools for microarrays,genetic linkage and association studies, and pharmacokinetics; tools to implement scannable forms andelectronic data capture; web portals for data entry and study monitoring; and a centralized MS SQL-serverdatabase for clinical research. Service to the institution includes statistical review of cancer-related clinicalresearch protocols. The core is directed by Jeffrey Longmate, PhD, Director of the Department ofBiostatistics. Co-Director is Joyce Niland, PhD, Director of the Clinical Protocol Management Core. The staffof the BC includes a large part of the department, and the BC enables their participation in Cancer Centerrelatedpilot projects and proposals, which may later develop into externally funded projects. The BC isdirectly involved in Cancer Center research from the inception of a research idea to the publication of results.The BC focuses heavily on clinical research, but also supports basic and translational research, as well assupporting several other cores. The BC collaborates continually with the Biomedical Informatics Core tooperate and further develop the MIDAS clinical research database, and regularly collaborates with membersof the Clinical Protocol Management Core to implement City of Hope-conducted or coordinated clinicalprotocols. In 2005, the BC was used by 80 CC members from all Programs, and logged 204 projects,including 21 grants naming BC personnel (7 multi-project grants), and 32 clinical protocols newly openedwith BC collaboration. Annual budget for the core is $2,651,640, with 62% from the institution, 34% othersources, and 4% ($100,100) requested from the CCSG.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA033572-25
Application #
7714130
Study Section
Subcommittee G - Education (NCI)
Project Start
2008-09-01
Project End
2012-11-30
Budget Start
2008-09-01
Budget End
2008-11-30
Support Year
25
Fiscal Year
2008
Total Cost
$71,000
Indirect Cost
Name
City of Hope/Beckman Research Institute
Department
Type
DUNS #
027176833
City
Duarte
State
CA
Country
United States
Zip Code
91010
Kirschbaum, Mark H; Frankel, Paul; Synold, Timothy W et al. (2018) A phase II study of vascular endothelial growth factor trap (Aflibercept, NSC 724770) in patients with myelodysplastic syndrome: a California Cancer Consortium Study. Br J Haematol 180:445-448
Zhang, Keqiang; Wang, Jinhui; Yang, Lu et al. (2018) Targeting histone methyltransferase G9a inhibits growth and Wnt signaling pathway by epigenetically regulating HP1? and APC2 gene expression in non-small cell lung cancer. Mol Cancer 17:153
Zhang, Bin; Nguyen, Le Xuan Truong; Li, Ling et al. (2018) Bone marrow niche trafficking of miR-126 controls the self-renewal of leukemia stem cells in chronic myelogenous leukemia. Nat Med 24:450-462
Moreira, Dayson; Adamus, Tomasz; Zhao, Xingli et al. (2018) STAT3 Inhibition Combined with CpG Immunostimulation Activates Antitumor Immunity to Eradicate Genetically Distinct Castration-Resistant Prostate Cancers. Clin Cancer Res 24:5948-5962
Liu, Liang; Yang, Lin; Yan, Wei et al. (2018) Chemotherapy Induces Breast Cancer Stemness in Association with Dysregulated Monocytosis. Clin Cancer Res 24:2370-2382
Woyach, Jennifer A; Ruppert, Amy S; Heerema, Nyla A et al. (2018) Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL. N Engl J Med 379:2517-2528
Wolfson, Julie A; Richman, Joshua S; Sun, Can-Lan et al. (2018) Causes of Inferior Outcome in Adolescents and Young Adults with Acute Lymphoblastic Leukemia: Across Oncology Services and Regardless of Clinical Trial Enrollment. Cancer Epidemiol Biomarkers Prev 27:1133-1141
Choi, Audrey H; O'Leary, Michael P; Chaurasiya, Shyambabu et al. (2018) Novel chimeric parapoxvirus CF189 as an oncolytic immunotherapy in triple-negative breast cancer. Surgery 163:336-342
Golfetto, Ottavia; Wakefield, Devin L; Cacao, Eliedonna E et al. (2018) A Platform To Enhance Quantitative Single Molecule Localization Microscopy. J Am Chem Soc 140:12785-12797
Aldoss, Ibrahim; Stiller, Tracey; Tsai, Ni-Chun et al. (2018) Therapy-related acute lymphoblastic leukemia has distinct clinical and cytogenetic features compared to de novo acute lymphoblastic leukemia, but outcomes are comparable in transplanted patients. Haematologica 103:1662-1668

Showing the most recent 10 out of 1396 publications